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&‘“-Methyl-L-arginine (L-NMA) and AJo-nitro-L-arginine (L-NNA) inhibited NO-induced cGMP accumulation in porcine aortic endothelial cells 
with half-maximally effective concentrations of 15 and 3.4,~M, respectively. The effects of both compounds were reversible, but the L-NNA-induced 
inhibition was only reversed by wash-out in the presence of 1 mM L-arginine. In short-term incubations (45 s) of membrane fractions, L-NMA 
and L-NNA exhibited similar potencies to inhibit endothelial NO synthase, but L-NNA was markedly more potent than L-NMA after prolonged 
incubation periods (2 3 min) due to induction of a pronounced, reversible nzyme inactivation. 
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1. INTRODUCTION 
Endothelium-derived nitric oxide (NO) is a potent 
endogenous vasodilator and inhibitor of platelet activa- 
tion [l]. NO release is probably mediated by intracellu- 
lar free Ca2+ required for activation of a constitutively 
expressed, calmodulin-dependent NO synthase (NOS) 
[2,3]. Whereas cytokine-inducible and neuronal 
isoforms of NOS are predominantly cytosolic [4,5], the 
endothelial enzyme is associated with membranes [6] 
due to posttranslational myristilation at its N-terminus 
[7,8]. Recently it has been shown that phosphorylation 
of endothelial NOS results in its translocation from 
membranes to the cytosol [9]. 
Albeit regulated in a quite different manner, all NOS 
isoforms described so far appear to be functionally and 
structurally similar (for reviews see: [lO-121). They are 
homodimers with subunit molecular masses ranging 
from 130 to 160 kDa and catalyze an oxidation of L- 
arginine to stoichiometrical amounts of L-citrulline and 
NO through reductive activation of molecular oxygen 
at their heme-containing catalytic domain. The elec- 
trons required for oxygen reduction are shuttled from 
the essential cofactor NADPH to the heme by the re- 
duced flavins FAD and FMN, suggesting that NOS 
isozymes exhibit combined cytochrome P450 oxygenase 
and reductase activities. In fact, neuronal NOS exhibits 
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Ca”lcalmodulin-dependent cytochrome reductase ac- 
tivity which seems to be independent from the catalytic 
site because it is neither affected by the substrate ana- 
logs L-NMA and L-NNA nor by drugs interfering with 
heme-catalyzed reactions [ 13,141. 
NOS-catalyzed reduction of molecular oxygen un- 
couples from L-arginine oxidation at low substrate con- 
centrations, leading to the generation of hydrogen per- 
oxide [15,16]. L-NMA has no effect on this L-arginine- 
independent reaction, but surprisingly L-NNA turned 
out as a powerful inhibitor of H,O, formation. Thus, 
L-NNA seems to have effects unrelated to substrate 
competition, and recently we found that it induced a 
rapid inactivation of brain NOS [14,17]. Previous re- 
ports indicate that L-NMA inhibits constitutive and 
inducible NOS with similar potencies, whereas L-NNA 
seems to exhibit selectivity for the endothelial and neu- 
ronal enzymes [18-201. These results suggest that L- 
NNA-induced enzyme inactivation may be specific for 
constitutive NOS. Since selective inhibition of NOS 
isozymes is of considerable therapeutical relevance, we 
have addressed this issue and studied the effects of L- 
NMA and L-NNA on endothelial NOS. We found that 
the endothelial enzyme is indeed reversibly inactivated 
by L-NNA, indicating that the catalytic domains of the 
two constitutive isozymes are closely similar but differ 
significantly from that of inducible NOS. 
2. MATERIALS AND METHODS 
2.1. Materials 
L-[2,3,4,5-‘H]Arginine hydrochloride (57 CYmmol) was from 
MedPro (Amersham), Vienna, Austria. All other chemicals were ob- 
tained from Sigma Deisenhofen, Germany or from sources described 
previously [13,15,21]. 
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2.2. Cell culture and determination of cGMP levels 
PAEC were cultured in 6-well plastic plates as described [21]. Prior 
to experiments, the cells were washed twice with isotonic HEPES 
buffer, pH 7.1, containing 2.5 mM CaCl, and 1 mM MgCl,, and 
preincubated for 15 min at 37°C in 1.4 ml of the same buffer in the 
presence of 1 mM 3-isobutyl-1-methylxanthine (IBMX), 1 PM in- 
domethacin and NOS inhibitors as indicated. For wash-out of inhib- 
itors, cells were incubated for further 15 min with or without 1 mM 
L-arginine and washed twice with buffer prior to starting the incuba- 
tions by addition of A 23,187 (1 PM final concentration). Reactions 
were terminated 4 min later by removal of the buffer and addition of 
1 ml of 0.01 M HCl. Cyclic GMP was measured in the supernatants 
by radioimmunoassay. 
2.3. Preparation of crude subcellular fractions from PAEC 
PAEC were suspended in a 50 mM triethanolamine/HCl buffer, pH 
7.0, containing 10 mM 2-mercaptoethanol and 0.5 mM EDTA (buffer 
A), and subsequent to addition of phenylmethylsulfonyl fluoride (0.5 
mM final concentration) the cells were sonicated (3 x 15 s) and centri- 
fuged at 100,000 x g for 40 min. The pellets were washed once with 
buffer A containing 1 M KC1 and then twice with buffer A without 
salt. Finally, pellets were suspended in buffer A, containing 10% (v/v) 
glycerol and stored at -70°C until use. Similarly, supernatants were 
adjusted to 10% glycerol prior to storage at -70°C. All procedures 
were carried out at 4°C. Protein was determined by the method of 
Bradford with bovine serum albumin as a standard [22]. 
To test for reversibility of NOS inhibition, cells were pretreated for 
5 min at 4°C in the absence and presence of 0.1 mM L-NMA or 
L-NNA (0.1 mM each) prior to homogenization and centrifugation 
at 100,000 x g for 20 min. The obtained pellets were washed three 
times with buffer A and finally resuspended irectly in the reaction 
mixture used for the determination of L-citrulline formation (see 
below). 
2.4. Determination of L-citrulline formation 
Unless otherwise indicated, subcellular fractions of PAEC (0.2-0.7 
mg of protein) were incubated for 10 min at 37°C in a total volume 
of 0.1 ml of a 50 mM triethanolamineJHC1 buffer, pH 7.0, containing 
3 PM free Ca”, 10 pg/ml calmodulin, 0.5 mM NADPH, 5 PM FMN, 
5 PM FAD, 10 PM (6R)-5,6,7,8-tetrahydrobiopterin, a d 10 PM L- 
[2,3,4,5-3H]arginine (- 90 nCi/nmol). Isolation of [‘Hlcitrulline was per- 
formed by column chromatography on Dowex cation exchange resin 
AG 5OW-X8 as previously described [23]. 
3. RESULTS AND DISCUSSION 
Formation of nitric oxide by cultured PAEC was as- 
sayed as Ca-ionophore A 23,187-induced accumulation 
of intracellular cGMP [21]. As shown in Fig. 1, cGMP 
formation was inhibited by L-NMA (A) and L-NNA 
(B) with I&, values of 15.0 and 3.4 ,uM, respectively. 
To find out whether inhibition was reversible, PAEC 
were pretreated with increasing concentrations of L- 
NMA or L-NNA and washed in the absence and pres- 
ence of 1 mM L-arginine prior to incubation with A 
23,187. Fig. 1 shows that the inhibitory effects of L- 
NMA were almost completely reversed after wash-out 
with buffer, whereas reversal of L-NNA-induced effects 
was only achieved with L-arginine additionally present. 
Thus, different molecular mechanisms eem to account 
for the inhibitory effects of L-NMA and L-NNA, but 
both compounds turned out as reversible inhibitors of 
endothelial NOS. The pronounced effect of added L- 
arginine shown in Fig. 1B should be due to competition 
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Fig. 1. Effects of L-NMA (A) and L-NNA (B) on A 23,187-stimulated 
accumulation of cGMP in PAEC. Cultured PAEC were preincubated 
for 15 min at 37°C with increasing concentrations of L-NMA (A) or 
L-NNA (B), incubated for 4 min in the presence of 1 PM A 23,187, 
and assayed for intracellular cGMP by radioimmunoassay as de- 
scribed in section 2. Where indicated, inhibitors were washed-out with 
buffer in the absence and presence of 1 mM L-arginine prior to incu- 
bation. Data are means f S.E. of three separate xperiments assayed 
in duplicate. 
with L-NNA at the substrate site of NOS, suggesting 
that intracellular L-arginine levels were considerably en- 
hanced by the exogenously added amino acid. Alterna- 
tively, it is also conceivable that the substrate may have 
direct access from the extracellular space to the catalytic 
domain of membrane-bound NOS. 
The data shown in Table I confirm the previous char- 
acterization of endothelial NOS as a membrane-associ- 
ated enzyme [6]. We found that KCl-insoluble fractions 
of PAEC contained 80-95% of total NOS with a specific 
activity ranging from 50 to 100 pm01 L-cit- 
rulline x mg-’ x min-‘, whereas NOS activity was 
below 5 pmol x mg-’ x min-’ in the supernatants. These 
results may explain the previously observed poor L- 
arginine-induced stimulation of purified soluble gua- 
nylyl cyclase co-incubated with PAEC cytosols [2]. 
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Table I 
Distribution of NOS in subcellular fractions of cultured PAEC 
Fraction Insoluble Soluble 
Protein (mg) 7.0 19.2 
Specific NOS activity 59.0 3.4 
(pm01 L-citrulline x mg-’ x min-‘) 
Total NOS activity 413 65.3 
(pm01 kcitrulline x min-‘) 
Distribution of NOS activity (%) 86 14 
Membranes and supematants were prepared and assayed for NOS 
activity and protein as described in section 2. Data are representative 
for 4 similar preparations. 
Fig. 2 shows the time courses of endothelial NOS 
inhibition by L-NMA and L-NNA (1 PM each), as- 
sayed as formation of L-citrulline from 10 PM L-argin- 
ine by PAEC membrane fractions. L-NMA inhibited 
the reaction in a time-independent manner to -70% of 
controls, whereas L-NNA induced a pronounced en- 
zyme inactivation down to - 30% of controls during the 
10 min of incubation. Both inhibitors were equally po- 
tent after short-term incubations (45 s), indicating that 
L-NMA and L-NNA have similar affinities to endothe- 
lial NOS and that the apparent high potency of L-NNA 
results from inactivation of the enzyme. Although the 
inhibitory effect of L-NMA was independent of time, 
our findings do not rule out the possibility that the 
endothelial enzyme metabolizes this compound to an as 
yet unidentified inactivating species as described for 
macrophage and brain NOS [17,24,25]. Metabolism of 
L-NMA is rather slow and enzyme inactivation could 
become substantial after prolonged periods of incuba- 
tion only. 
Reversibility of enzyme inactivation was studied by 
determination of NOS activities in membrane fractions 
obtained from PAEC pretreated with L-NNA or L- 
NMA (0.1 mM each) and comparing the data with the 
respective enzyme activities of untreated preparations. 
The data shown in Table II demonstrate that the effects 
of both compounds were reversed when the membranes 
were washed with buffer, albeit reversibility of L-NNA- 
induced inhibition was not complete even when 1 mM 
L-arginine had been included during wash-out of the 
inhibitor (n = 2; data not shown). This latter finding is 
not necessarily in conflict with the results obtained with 
intact cells (Fig. lB), since experimental conditions are 
hardly comparable. Due to instability of endothelial 
NOS under cell-free conditions, we had to rapidly equil- 
ibrate and wash-out the membranes at 4’C, while re- 
moval of the inhibitors from intact cells was performed 
at 37°C for more extended periods of time. Recently we 
found that dissociation of L-NNA from purified brain 
NOS followed first order kinetics with a remarkably 
slow rate constant of 7.4 x lo-* min-’ [17]. Thus, disso- 
ciation of L-NNA from both constitutive isozymes 
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Fig. 2. Time course of endothelial NOS inhibition by L-NMA and 
L-NNA. Membrane fractions (0.7 mg of protein) obtained from cul- 
tured PAEC were incubated at 37°C in a 50 mM triethanolamine/HCl 
buffer, pH 7.0, containing 3 PM free Ca*‘, 10 &ml calmodulin, 0.5 
mM NADPH, 5 PM FMN, 5 PM FAD, 10 PM (6R)-5,6,7,8-tetrahy- 
drobiopterin, and 10 PM L-[2,3,4,5-3H]arginine (- 90 nCi/nmol) in the 
absence and presence of L-NMA and L-NNA (1 ,uM each). At the 
indicated time points, 0.1 ml aliquots were removed and assayed for 
[3HJcitrulline. Data are means + S.E. of three separate experiments 
assayed in duplicate. 
seems to be slower than that of L-NMA, and this may 
be the reason why L-NNA has been described as irre- 
versible inhibitor of constitutive NOS [26]. 
Together with previous results [17], the present find- 
ings indicate that similar mechanisms may account for 
inhibition of endothelial and neuronal NOS by L-NNA. 
Both enzymes undergo substantial inactivation in the 
presence of this drug, and the effect is clearly reversible, 
even though rates of dissociation are rather slow. How- 
ever, NOS present in cytosolic fractions of y-interferon/ 
LPS-activated RAW-264.7 macrophages was not inhib- 
ited by L-NNA in the presence of equimolar amounts 
of L-arginine (B. Mayer, unpublished observation), con- 
firming that the inducible enzyme is considerably less 
sensitive to inhibition by this compound than constitu- 
Table II 
Reversibility of endothelial NOS inhibition by L-NMA and L-NNA 
Incubation NOS activity (% of untreated controls) 
L-NMA-pretreated L-NNA-pretreated 
Buffer 106.9 +- 7.66 58.4 + 6.05 
Inhibitor (10 PM) 26.2 + 2.73 4.4 2 1.04 
PAEC were pretreated with L-NMA or L-NNA (0.1 mM each) for 10 
min at 4°C. Membrane fractions, prepared and washed as described 
in section 2, were assayed for NOS activity in the absence and presence 
of 10pM of the respective inhibitors. Controls (= 100%) refer to NOS 
activities of membranes obtained from untreated cells determined in 
the absence of inhibitors. Data are means + SE. of three preparations 
assayed in duplicate. 
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tive NOS [19,20]. The pronounced L-NNA-induced in- 
activation we have seen appears to be specific, therefore, 
for the endothelial and neuronal enzymes, suggesting 
that the catalytic sites of the constitutive isozymes truc- 
turally differ from the substrate binding domain of in- 
ducible NOS. 
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